Your browser doesn't support javascript.
loading
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg, Jonathan E; Hoffman-Censits, Jean; Powles, Tom; van der Heijden, Michiel S; Balar, Arjun V; Necchi, Andrea; Dawson, Nancy; O'Donnell, Peter H; Balmanoukian, Ani; Loriot, Yohann; Srinivas, Sandy; Retz, Margitta M; Grivas, Petros; Joseph, Richard W; Galsky, Matthew D; Fleming, Mark T; Petrylak, Daniel P; Perez-Gracia, Jose Luis; Burris, Howard A; Castellano, Daniel; Canil, Christina; Bellmunt, Joaquim; Bajorin, Dean; Nickles, Dorothee; Bourgon, Richard; Frampton, Garrett M; Cui, Na; Mariathasan, Sanjeev; Abidoye, Oyewale; Fine, Gregg D; Dreicer, Robert.
Affiliation
  • Rosenberg JE; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: rosenbj1@mskcc.org.
  • Hoffman-Censits J; Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA.
  • Powles T; Barts Cancer Institute ECMC, Barts Health and the Royal Free NHS Trust, Queen Mary University of London, London, UK.
  • van der Heijden MS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Balar AV; Genitourinary Cancers Program, Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY, USA.
  • Necchi A; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Dawson N; Medstar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • O'Donnell PH; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.
  • Balmanoukian A; The Angeles Clinic and Research Institute, Los Angeles, CA, USA.
  • Loriot Y; Department of Cancer Medicine, Gustave-Roussy Cancer Campus, Villejuif, University of Paris Sud, Paris, France.
  • Srinivas S; Division of Oncology/Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Retz MM; Department of Urology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
  • Grivas P; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Joseph RW; Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA.
  • Galsky MD; Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA.
  • Fleming MT; Virginia Oncology Associates, US Oncology Research, Norfolk, VA, USA.
  • Petrylak DP; Smilow Cancer Center, Yale University, New Haven, CT, USA.
  • Perez-Gracia JL; Department of Oncology, Clínica Universidad de Navarra, University of Navarra, Pamplona, Navarre, Spain.
  • Burris HA; Sarah Cannon Research Institute, Nashville, TN, USA; Tennessee Oncology, Nashville, TN, USA.
  • Castellano D; Medical Oncology Department, Genitourinary Oncology Unit, University Hospital 12 de Octubre, Madrid, Spain.
  • Canil C; Division of Medical Oncology, Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.
  • Bellmunt J; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Bajorin D; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Nickles D; Genentech Inc, 1 DNA Way, South San Francisco, CA, USA.
  • Bourgon R; Genentech Inc, 1 DNA Way, South San Francisco, CA, USA.
  • Frampton GM; Foundation Medicine Inc, Cambridge, MA, USA.
  • Cui N; Genentech Inc, 1 DNA Way, South San Francisco, CA, USA.
  • Mariathasan S; Genentech Inc, 1 DNA Way, South San Francisco, CA, USA.
  • Abidoye O; Genentech Inc, 1 DNA Way, South San Francisco, CA, USA.
  • Fine GD; Genentech Inc, 1 DNA Way, South San Francisco, CA, USA.
  • Dreicer R; Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA.
Lancet ; 387(10031): 1909-20, 2016 May 07.
Article in En | MEDLINE | ID: mdl-26952546
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urologic Neoplasms / B7-H1 Antigen / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Lancet Year: 2016 Document type: Article Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urologic Neoplasms / B7-H1 Antigen / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Lancet Year: 2016 Document type: Article Country of publication: United kingdom